Compare XNET & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNET | OABI |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.4M | 294.3M |
| IPO Year | 2011 | 2021 |
| Metric | XNET | OABI |
|---|---|---|
| Price | $4.93 | $4.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 219.1K | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $0.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.52 | $1.32 |
| 52 Week High | $11.03 | $4.93 |
| Indicator | XNET | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 72.78 |
| Support Level | $4.78 | $1.71 |
| Resistance Level | $6.09 | N/A |
| Average True Range (ATR) | 0.19 | 0.30 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 35.71 | 68.10 |
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.